U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06860789) titled 'AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)' on Feb. 25.
Brief Summary: A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AK135 for the treatment of chemotherapy-induced peripheral neuropathy in patients with malignant tumor
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Intervention:
DRUG: AK135
IV infusion, specified dose with specified treatment frequency
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Akeso
Published by HT Digital Cont...